Emcure Pharmaceuticals Ltd (EMCURE) - Total Assets
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) holds total assets worth Rs93.93 Billion INR (≈ $1.02 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Emcure Pharmaceuticals Ltd for net asset value and shareholders' equity analysis.
Emcure Pharmaceuticals Ltd - Total Assets Trend (2022–2025)
This chart illustrates how Emcure Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data.
Emcure Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Emcure Pharmaceuticals Ltd's total assets of Rs93.93 Billion consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.5% |
| Accounts Receivable | Rs20.55 Billion | 25.0% |
| Inventory | Rs19.32 Billion | 23.5% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs5.79 Billion | 7.0% |
| Goodwill | Rs3.68 Billion | 4.5% |
Asset Composition Trend (2022–2025)
This chart illustrates how Emcure Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Emcure Pharmaceuticals Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Emcure Pharmaceuticals Ltd's current assets represent 55.3% of total assets in 2025, a decrease from 56.5% in 2022.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2025, up from 1.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 5.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 25.0% of total assets.
Emcure Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Emcure Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF21.61 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Emcure Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 1.57 | 1.34 |
| Quick Ratio | 0.90 | 0.95 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs19.19 Billion | Rs16.24 Billion | Rs9.90 Billion |
Emcure Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Emcure Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.42 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | Rs82.33 Billion |
| Market Capitalization | $3.68 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Emcure Pharmaceuticals Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Emcure Pharmaceuticals Ltd's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Emcure Pharmaceuticals Ltd (2022–2025)
The table below shows the annual total assets of Emcure Pharmaceuticals Ltd from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs82.33 Billion ≈ $890.34 Million |
+5.46% |
| 2024-03-31 | Rs78.06 Billion ≈ $844.21 Million |
+16.99% |
| 2023-03-31 | Rs66.73 Billion ≈ $721.61 Million |
+10.04% |
| 2022-03-31 | Rs60.63 Billion ≈ $655.74 Million |
-- |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more